BTOG 2019 | Targeting the tumor vasculature in mesothelioma

An interesting therapeutic strategy being investigated for mesothelioma is targeting the tumor vasculature, as discussed here by Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK. Prof. Fennell highlights the MAPS trial (NCT00651456) of the angiogenic inhibitor bevacizumab, and explains how the international umbrella study of Mesothelioma Stratified Therapy (MiST) and BEAT-meso study (NCT03762018) for malignant pleural mesothelioma will be investigating the synergy of these agents with immunotherapy. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.